News & Updates

For patients with severe alopecia areata who achieved meaningful hair regrowth with 1-year course of baricitinib, subsequent discontinuation appears to reverse treatment gains, highlighting the need for ongoing therapy.

Treatment with carboplatin-paclitaxel (CP) plus atezolizumab results in better quality-adjusted survival in patients with advanced or recurrent endometrial cancer (EC) as compared with CP alone, according to a post hoc analysis of the AtTEnd/ENGOT-EN7 trial.

In a systematic review and individual participant data (IPD) meta-analysis, the use of oral corticosteroids (OCS) improves short-term outcomes in children aged 12–71 months with acute preschool wheeze, more so among children with previous wheeze or asthma and those with moderate-to-severe acute wheeze.

Nearly one in two young men with primary psychogenic erectile dysfunction (ED) treated with tadalafil 5 mg once daily achieve spontaneous medication-free erectile function (EF) at 3 months, as shown in a study. Younger patients tend to have a higher chance of recovery after drug discontinuation.

In untreated myelofibrosis, using navitoclax in combination with ruxolitinib appears to result in a twofold increase in the number of patients experiencing spleen volume shrinkage, regardless of prognosis, according to updated data from the phase III TRANSFORM-1 trial.

Up to 3 months of treatment with adjunctive brexpiprazole helps with symptom severity in Asian adults with major depressive disorder (MDD) and inadequate response to antidepressants in a real-life clinical setting in Singapore.